메뉴 건너뛰기




Volumn 15, Issue 5, 1997, Pages 2135-2138

Prevention of acute emesis in cancer patients following high-dose cisplatin with the combination of oral dolasetron and dexamethasone

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DEXAMETHASONE; DOLASETRON MESILATE;

EID: 0030978001     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.5.2135     Document Type: Article
Times cited : (27)

References (24)
  • 1
    • 0028354474 scopus 로고
    • Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin
    • Kris MG, Grunberg SM, Gralla RJ, et al: Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin. J Clin Oncol 12:1045-1049, 1994
    • (1994) J Clin Oncol , vol.12 , pp. 1045-1049
    • Kris, M.G.1    Grunberg, S.M.2    Gralla, R.J.3
  • 2
    • 9444264707 scopus 로고    scopus 로고
    • Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer
    • Hesketh P, Navari R, Grote T, et al: Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. J Clin Oncol 14:2242-2249, 1996
    • (1996) J Clin Oncol , vol.14 , pp. 2242-2249
    • Hesketh, P.1    Navari, R.2    Grote, T.3
  • 3
    • 84871470345 scopus 로고
    • Development, implementation and assessment of antiemetic guidelines
    • abstr
    • Nolle J, Lucarelli C, Baltzer L, et al: Development, implementation and assessment of antiemetic guidelines. Proc Am Soc Clin Oncol 14:527, 1995 (abstr)
    • (1995) Proc Am Soc Clin Oncol , vol.14 , pp. 527
    • Nolle, J.1    Lucarelli, C.2    Baltzer, L.3
  • 4
    • 0025008191 scopus 로고
    • Antagonism of serotonin S3 receptors with ondansetron prevents nausea and emesis induced by cyclophosphamide-containing chemotherapy regimens
    • Cubeddu LX, Hoffman IS, Fuenmayor NT, et al: Antagonism of serotonin S3 receptors with ondansetron prevents nausea and emesis induced by cyclophosphamide-containing chemotherapy regimens. J Clin Oncol 8:1721-1727, 1990
    • (1990) J Clin Oncol , vol.8 , pp. 1721-1727
    • Cubeddu, L.X.1    Hoffman, I.S.2    Fuenmayor, N.T.3
  • 5
    • 0025732890 scopus 로고
    • Evaluation of three oral dosages of ondansetron in the prevention of nausea chemotherapy
    • Fraschini G, Ciociola A, Esparza L, et al: Evaluation of three oral dosages of ondansetron in the prevention of nausea chemotherapy. J Clin Oncol 9:1268-1274, 1991
    • (1991) J Clin Oncol , vol.9 , pp. 1268-1274
    • Fraschini, G.1    Ciociola, A.2    Esparza, L.3
  • 6
    • 0027414795 scopus 로고
    • Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy
    • Beck TM, Ciociola AA, Jones SE, et al: Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy. Ann Intern Med 118:407-413, 1993
    • (1993) Ann Intern Med , vol.118 , pp. 407-413
    • Beck, T.M.1    Ciociola, A.A.2    Jones, S.E.3
  • 7
    • 0028100688 scopus 로고
    • Oral granisetron alone and in combination with dexamethasone: A double-blind randomized comparison against high-dose metoclopramide plus dexamethasone in prevention of cisplatin-induced emesis
    • Heron J, Goedhals L, Jordaan J, et al: Oral granisetron alone and in combination with dexamethasone: A double-blind randomized comparison against high-dose metoclopramide plus dexamethasone in prevention of cisplatin-induced emesis. Ann Oncol 5:579-584, 1994
    • (1994) Ann Oncol , vol.5 , pp. 579-584
    • Heron, J.1    Goedhals, L.2    Jordaan, J.3
  • 8
    • 0037740408 scopus 로고    scopus 로고
    • Determination of optimal dolasetron mesylate (DM) dose in prevention of acute nausea and vomiting (ANV) after moderately emetogenic chemotherapy (MECT) using pooled data from three pivotal trials
    • abstr
    • Rubenstein E, Fauser A, Grote T, et al: Determination of optimal dolasetron mesylate (DM) dose in prevention of acute nausea and vomiting (ANV) after moderately emetogenic chemotherapy (MECT) using pooled data from three pivotal trials. Proc Am Soc Clin Oncol 15:532, 1996 (abstr)
    • (1996) Proc Am Soc Clin Oncol , vol.15 , pp. 532
    • Rubenstein, E.1    Fauser, A.2    Grote, T.3
  • 9
    • 0021194346 scopus 로고
    • Dexamethasone and high dose metoclopramide: Efficacy in controlling cisplatin induced nausea and vomiting
    • Allan SG, Cornbleet MA, Warrington PS, et al: Dexamethasone and high dose metoclopramide: Efficacy in controlling cisplatin induced nausea and vomiting. Br Med J 289:878-879, 1984
    • (1984) Br Med J , vol.289 , pp. 878-879
    • Allan, S.G.1    Cornbleet, M.A.2    Warrington, P.S.3
  • 10
    • 0021993784 scopus 로고
    • Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine. Results of consecutive trials in 255 patients
    • Kris MG, Gralla RJ, Tyson LB, et al: Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine. Results of consecutive trials in 255 patients. Cancer 55:527-534, 1985
    • (1985) Cancer , vol.55 , pp. 527-534
    • Kris, M.G.1    Gralla, R.J.2    Tyson, L.B.3
  • 11
    • 0022902689 scopus 로고
    • Comparison of metoclopramide and metoclopramide plus dexamethasone for complete protection from cisplatinum-induced emesis
    • Grunberg SM, Akerley WA, Krailo MD, et al: Comparison of metoclopramide and metoclopramide plus dexamethasone for complete protection from cisplatinum-induced emesis. Cancer Invest 4:379-385, 1986
    • (1986) Cancer Invest , vol.4 , pp. 379-385
    • Grunberg, S.M.1    Akerley, W.A.2    Krailo, M.D.3
  • 12
    • 0028888664 scopus 로고
    • Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer
    • Roila F: Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 332:1-5, 1995
    • (1995) N Engl J Med , vol.332 , pp. 1-5
    • Roila, F.1
  • 13
    • 0026071703 scopus 로고
    • Prevention of cisplatin-induced emesis: A double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone
    • Roila F, Tonato M, Cognetti F, et al: Prevention of cisplatin-induced emesis: A double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol 9:675-678, 1991
    • (1991) J Clin Oncol , vol.9 , pp. 675-678
    • Roila, F.1    Tonato, M.2    Cognetti, F.3
  • 15
    • 0342573086 scopus 로고    scopus 로고
    • Addition of the dopamine D2 antagonist prochlorperazine to granisetron/dexamethasone: Improved control of acute emesis fron high-dose cisplatin
    • abstr
    • Hesketh PJ, Gandara DR, Hainsworth J, et al: Addition of the dopamine D2 antagonist prochlorperazine to granisetron/dexamethasone: Improved control of acute emesis fron high-dose cisplatin. Proc Am Soc Clin Oncol 15:540, 1996 (abstr)
    • (1996) Proc Am Soc Clin Oncol , vol.15 , pp. 540
    • Hesketh, P.J.1    Gandara, D.R.2    Hainsworth, J.3
  • 16
    • 0022412283 scopus 로고
    • Consecutive dose-finding trials adding lorazepam to the combination of metoclopramide plus dexamethasone: Improved subjective effectiveness over the combination of diphenhydramine plus metoclopramide plus dexamethasone
    • Kris MG, Gralla RJ, Clark RA, et al: Consecutive dose-finding trials adding lorazepam to the combination of metoclopramide plus dexamethasone: Improved subjective effectiveness over the combination of diphenhydramine plus metoclopramide plus dexamethasone. Cancer Treat Rep 69:1257-1262, 1985
    • (1985) Cancer Treat Rep , vol.69 , pp. 1257-1262
    • Kris, M.G.1    Gralla, R.J.2    Clark, R.A.3
  • 17
    • 0023230562 scopus 로고
    • Antiemetic control and prevention of side effects of anti-cancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide plus dexamethasone. A double-blind, randomized trial
    • Kris MG, Gralla RJ, Clark RA, et al: Antiemetic control and prevention of side effects of anti-cancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide plus dexamethasone. A double-blind, randomized trial. Cancer 60:2816-2822, 1987
    • (1987) Cancer , vol.60 , pp. 2816-2822
    • Kris, M.G.1    Gralla, R.J.2    Clark, R.A.3
  • 18
    • 0343878715 scopus 로고
    • A correlation of objective (OBJ) and subjective (SUBJ) parameters in assessing antiemetic regimens (AER)
    • abstr
    • Clark R, Tyson L, Frisone M: A correlation of objective (OBJ) and subjective (SUBJ) parameters in assessing antiemetic regimens (AER). Oncol Nurs Forum 12:96, 1985 (suppl; abstr)
    • (1985) Oncol Nurs Forum , vol.12 , Issue.SUPPL. , pp. 96
    • Clark, R.1    Tyson, L.2    Frisone, M.3
  • 19
    • 0029154962 scopus 로고
    • Adjusting the dose of intravenous ondansetron plus dexamethasone to the emetic potential of the chemotherapy regimen
    • Hesketh P, Beck T, Uhlenhopp M, et al: Adjusting the dose of intravenous ondansetron plus dexamethasone to the emetic potential of the chemotherapy regimen. J Clin Oncol 13:2117-2122, 1995
    • (1995) J Clin Oncol , vol.13 , pp. 2117-2122
    • Hesketh, P.1    Beck, T.2    Uhlenhopp, M.3
  • 20
    • 0024496307 scopus 로고
    • Phase II trials of the serotonin antagonist GR38032F for the control of vomiting caused by cisplatin
    • Kris MG, Gralla RJ, Clark RA, et al: Phase II trials of the serotonin antagonist GR38032F for the control of vomiting caused by cisplatin. J Natl Cancer Inst 81:42-46, 1989
    • (1989) J Natl Cancer Inst , vol.81 , pp. 42-46
    • Kris, M.G.1    Gralla, R.J.2    Clark, R.A.3
  • 21
    • 0024347758 scopus 로고
    • GR 38032F (GRC507/75): A novel compound effective in the prevention of acute cisplatin-induced emesis
    • Hesketh PJ, Murphy WK, Lester EP, et al: GR 38032F (GRC507/75): A novel compound effective in the prevention of acute cisplatin-induced emesis. J Clin Oncol 7:700-705, 1989
    • (1989) J Clin Oncol , vol.7 , pp. 700-705
    • Hesketh, P.J.1    Murphy, W.K.2    Lester, E.P.3
  • 22
    • 0025108531 scopus 로고
    • Ondansetron for the prevention of emesis induced by high-dose cisplatin. A multicenter dose-response study
    • Khojasteh A, Sartiano G, Tapazoglou E, et al: Ondansetron for the prevention of emesis induced by high-dose cisplatin. A multicenter dose-response study. Cancer 66:1101-1105, 1990
    • (1990) Cancer , vol.66 , pp. 1101-1105
    • Khojasteh, A.1    Sartiano, G.2    Tapazoglou, E.3
  • 23
    • 0025192890 scopus 로고
    • Comparison of the 5-hydroxytryptamine 3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis
    • Marty M, Pouillart P, Scholl S, et al: Comparison of the 5-hydroxytryptamine 3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med 322:816-821, 1990
    • (1990) N Engl J Med , vol.322 , pp. 816-821
    • Marty, M.1    Pouillart, P.2    Scholl, S.3
  • 24
    • 0025615002 scopus 로고
    • Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting
    • De Mulder PHM, Seynaeve C, Vermorken JB, et al: Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. Ann Intern Med 113:834-840, 1990
    • (1990) Ann Intern Med , vol.113 , pp. 834-840
    • De Mulder, P.H.M.1    Seynaeve, C.2    Vermorken, J.B.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.